Publication details

Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma

Authors	LUIJTEN Maartje M W JAN van Weelden Willem LALISANG Roy I BULTEN Johan LINDEMANN Kristina VAN BEEKHUIZEN Heleen J TRUM Hans BOLL Dorry WERNER Henrica M J VAN LONKHUIJZEN Luc R C W YIGIT Refika KRAKSTAD Camilla WITTEVEEN Petronella O GALAAL Khadra VAN GINKEL Alexandra A BIGNOTTI Eliana WEINBERGER Vít SWEEGERS Sanne ERIKSSON Ane Gerda Z KEIZER Diederick M ANJA van de Stolpe ROMANO Andrea PIJNENBORG Johanna M A
Year of publication	2024
Type	Article in Periodical
Magazine / Source	Cancers
MU Faculty or unit	Faculty of Medicine
Citation
web	https://www.mdpi.com/2072-6694/16/11/2084
Doi	http://dx.doi.org/10.3390/cancers16112084
Keywords	endometrial cancer; hormone receptor; tumour location
Description	Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC > 50% cases. ER/PR-IHC can vary by tumour location and is frequently lost with tumour progression. Therefore, we explored the relationship between ER/PR-IHC expression and tumour location in EC. Methods: Pre-treatment tumour biopsies from 6 different sites of 80 cases treated with hormonal therapy were analysed for ER/PR-IHC expression and classified into categories 0-10%, 10-50%, and >50%. The ER pathway activity score (ERPAS) was determined based on mRNA levels of ER-related target genes, reflecting the actual activity of the ER receptor. Results: There was a trend towards lower PR-IHC (33% had PR > 50%) and ERPAS (27% had ERPAS > 15) in lymphogenic metastases compared to other locations (p = 0.074). Hematogenous and intra-abdominal metastases appeared to have high ER/PR-IHC and ERPAS (85% and 89% ER-IHC > 50%; 64% and 78% PR-IHC > 50%; 60% and 71% ERPAS > 15, not significant). Tumour grade and previous radiotherapy did not affect ER/PR-IHC or ERPAS. Conclusions: A trend towards lower PR-IHC and ERPAS was observed in lymphogenic sites. Verification in larger cohorts is needed to confirm these findings, which may have implications for the use of hormonal therapy in the future.